Revolutionizing Oncology: Servier India Launches Precision Cancer Therapy
Servier India announced the launch of Ivosidenib (Tibsovo®), a targeted therapy for Acute Myeloid Leukemia (AML) and Cholangiocarcinoma patients with IDH1 mutation. This significant advancement in cancer treatment will improve outcomes and quality of life in India, addressing the urgent need for innovative therapies.
- Country:
- India
In a groundbreaking development for oncology in India, Servier India recently launched Ivosidenib (Tibsovo®), an oral targeted therapy aimed at treating cancer patients with Acute Myeloid Leukemia (AML) and Cholangiocarcinoma harboring the isocitrate dehydrogenase-1 (IDH1) mutation.
This announcement, coinciding with AML Awareness Month, underscores Servier India's effort to extend advanced cancer treatments to patients grappling with rare and challenging malignancies. Significant gaps in cancer care, such as the low percentage of AML patients receiving adequate treatment, are anticipated to be addressed with this launch, ultimately improving patient survival and quality of life.
With around 7–14% of AML patients carrying the IDH1 mutation, the new therapy represents a significant leap toward precision medicine in oncology. Servier India's collaboration with healthcare providers and patient groups aims to ensure wide accessibility and affordability of this essential treatment across the country.
(With inputs from agencies.)
Google News